Ghulam Rehman Mohyuddin, MD, discusses improving survival for patients with multiple myeloma.
Ghulam Rehman Mohyuddin, MD, chief resident, Internal Medicine, University of Kansas, discusses improving survival for patients with multiple myeloma.
Over the past decades, novel therapies have improved the average survival of patients with multiple myeloma, says Mohyuddin. For example, proteasome inhibitors, immunomodulatory agents, and most recently, BCMA-directed therapies have emerged as treatment options in myeloma. Additionally, the novel XPO1 inhibitor selinexor (Xpovio) was approved in 2019 for patients with heavily pretreated relapsed/refractory disease. In the near future, CAR T-cell therapy could gain FDA approval in multiple myeloma, offering another option to patients, Mohyuddin explains.
The introduction of these options, among others, has significantly improved survival for patients. Currently, patients with standard-risk multiple myeloma are expected to live at least 10 years after diagnosis, concludes Mohyuddin.